In the claims:

1-20. (Canceled)

- 21. (Currently amended) A method for inhibiting tumor growth in a subject bearing a tumor, which comprises administering to the subject a nucleotide sequence in a carrier, wherein the administered nucleotide sequence inhibits tumor angiogenesis in said subject and thereby inhibits growth of said tumor and RNA encoding at least one anti-angiogenic protein or peptide in a carrier whereby the RNA is expressed and tumor growth is inhibited, wherein the carrier is selected from the group consisting of liposomes, cationic polymers, micelles and a combination thereof.
- 22. (Currently amended) The method of claim 21, wherein the <u>nucleotide sequence</u> RNA and carrier are administered via intravenous injection.
- 23. (Previously presented) The method of claim 21, wherein the carrier is a liposomal carrier.
- 24. (Previously presented) The method of claim 21, wherein the carrier is a cationic polymer carrier.
- 25. (Previously presented) The method of claim 21, wherein the carrier is a micelle carrier.
- 26. (Currently amended) A method for providing anti-angiogenic therapy to a subject in need thereof, which comprises administering by injection to the subject a nucleotide sequence in a carrier, wherein the administered nucleotide sequence inhibits angiogenic growth and RNA encoding at least one anti-angiogenic protein or peptide in a carrier whereby the RNA is expressed and angiogenic growth is inhibited, wherein the carrier is selected from the group consisting of liposomes, cationic polymers, micelles and a combination thereof.
- 27. (Previously presented) The method of claim 26, wherein the injection is intravenous injection.

- 28. (Previously presented) The method of claim 26, wherein the injection is made into a tumor in the subject.
- 29. (Previously presented) The method of claim 26, wherein the carrier is a liposomal carrier.
- 30. (Previously presented) The method of claim 26, wherein the carrier is a cationic polymer carrier.
- 31. (Previously presented) The method of claim 26, wherein the carrier is a micelle carrier.
- 32. (Previously presented) The method of claim 21, further comprising administering nucleic acid encoding a tumor suppressor protein.
- 33. (Previously presented) The method of claim 32, wherein the tumor suppressor protein is p53.
- 34. (Previously presented) The method of claim 26, further comprising administering nucleic acid encoding a tumor suppressor protein.
- 35. (Previously presented) The method of claim 34, wherein the tumor suppressor protein is p53.

36-40. (Canceled)

41. (New) The method of claim 21, wherein said administration is into said tumor.